Literature DB >> 26641802

Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous Disease.

Barbara P Barna1, Matthew McPeek1, Anagha Malur1, Michael B Fessler2, Christopher J Wingard3, Larry Dobbs4, Kathryn M Verbanac5, Mark Bowling1, Marc A Judson6, Mary Jane Thomassen1.   

Abstract

We established a murine model of multiwall carbon nanotube (MWCNT)-induced chronic granulomatous disease, which resembles human sarcoidosis pathology. At 60 days after oropharyngeal MWCNT instillation, bronchoalveolar lavage (BAL) cells from wild-type mice exhibit an M1 phenotype with elevated proinflammatory cytokines and reduced peroxisome proliferator-activated receptor γ (PPARγ)-characteristics also present in human sarcoidosis. Based upon MWCNT-associated PPARγ deficiency, we hypothesized that the PPARγ target gene, ATP-binding cassette (ABC) G1, a lipid transporter with antiinflammatory properties, might also be repressed. Results after MWCNT instillation indicated significantly repressed ABCG1, but, surprisingly, lipid transporter ABCA1 was also repressed, suggesting a possible second pathway. Exploration of potential regulators revealed that microRNA (miR)-33, a lipid transporter regulator, was strikingly elevated (13.9 fold) in BAL cells from MWCNT-instilled mice but not sham control mice. Elevated miR-33 was also detected in murine granulomatous lung tissue. In vitro studies confirmed that lentivirus-miR-33 overexpression repressed both ABCA1 and ABCG1 (but not PPARγ) in cultured murine alveolar macrophages. BAL cells of patients with sarcoidosis also displayed elevated miR-33 together with reduced ABCA1 and ABCG1 messenger RNA and protein compared with healthy control subjects. Moreover, miR-33 was elevated within sarcoidosis granulomatous tissue. The findings suggest that alveolar macrophage miR-33 is up-regulated by proinflammatory cytokines and may perpetuate chronic inflammatory granulomatous disease by repressing antiinflammatory functions of ABCA1 and ABCG1 lipid transporters. The results also suggest two possible pathways for transporter dysregulation in granulomatous disease-one associated with intrinsic PPARγ status and the other with miR-33 up-regulation triggered by environmental challenges, such as MWCNT.

Entities:  

Keywords:  carbon nanotube; lipid transporters; microRNA; murine model; sarcoidosis

Mesh:

Substances:

Year:  2016        PMID: 26641802      PMCID: PMC4942222          DOI: 10.1165/rcmb.2015-0332OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  30 in total

1.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

2.  ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung.

Authors:  David W Draper; Jennifer H Madenspacher; Darlene Dixon; Debra H King; Alan T Remaley; Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

3.  Emerging roles for cholesterol and lipoproteins in lung disease.

Authors:  Kymberly M Gowdy; Michael B Fessler
Journal:  Pulm Pharmacol Ther       Date:  2012-06-15       Impact factor: 3.410

4.  Pulmonary abnormalities due to ABCA1 deficiency in mice.

Authors:  Sandra R Bates; Jian-Qin Tao; Heidi L Collins; Omar L Francone; George H Rothblat
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-07-29       Impact factor: 5.464

5.  MiR-33 contributes to the regulation of cholesterol homeostasis.

Authors:  Katey J Rayner; Yajaira Suárez; Alberto Dávalos; Saj Parathath; Michael L Fitzgerald; Norimasa Tamehiro; Edward A Fisher; Kathryn J Moore; Carlos Fernández-Hernando
Journal:  Science       Date:  2010-05-13       Impact factor: 47.728

6.  Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases.

Authors:  Kathryn Mary Verbanac; Christopher Justus Min; Ann Elizabeth Mannie; Jianfen Lu; Kevin F O'Brien; Martin Rosman; Lorraine Tafra
Journal:  Ann Surg Oncol       Date:  2010-09-19       Impact factor: 5.344

7.  The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor.

Authors:  Chongren Tang; Yuhua Liu; Peter S Kessler; Ashley M Vaughan; John F Oram
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

Review 8.  Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus?

Authors:  A A Shvedova; E R Kisin; D Porter; P Schulte; V E Kagan; B Fadeel; V Castranova
Journal:  Pharmacol Ther       Date:  2008-12-06       Impact factor: 12.310

Review 9.  Involvement of microRNAs in physiological and pathological processes in the lung.

Authors:  Tereza Tomankova; Martin Petrek; Eva Kriegova
Journal:  Respir Res       Date:  2010-11-23

Review 10.  Alveolar macrophages: plasticity in a tissue-specific context.

Authors:  Tracy Hussell; Thomas J Bell
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

View more
  15 in total

1.  Peroxisome Proliferator-activated Receptor-γ Deficiency Exacerbates Fibrotic Response to Mycobacteria Peptide in Murine Sarcoidosis Model.

Authors:  Anagha Malur; Arjun Mohan; Robert A Barrington; Nancy Leffler; Amrita Malur; Barbara Muller-Borer; Gina Murray; Kim Kew; Chuanzhen Zhou; Josh Russell; Jacob L Jones; Christopher J Wingard; Barbara P Barna; Mary Jane Thomassen
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

Review 2.  Molecular profiling in sarcoidosis.

Authors:  Nicholas K Arger; Brian O'Connor; Laura L Koth
Journal:  Curr Opin Pulm Med       Date:  2020-09       Impact factor: 3.155

Review 3.  A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease.

Authors:  Michael B Fessler
Journal:  Ann Am Thorac Soc       Date:  2017-11

4.  Alveolar Macrophage ABCG1 Deficiency Promotes Pulmonary Granulomatous Inflammation.

Authors:  Matthew McPeek; Anagha Malur; Debra A Tokarz; Kvin Lertpiriyapong; Kymberly M Gowdy; Gina Murray; Christopher J Wingard; Michael B Fessler; Barbara P Barna; Mary Jane Thomassen
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

5.  Thrombospondin-1 and microRNA-1 expression in response to multiwalled carbon nanotubes in alveolar epithelial cells.

Authors:  M Pacurari; R Kafoury; T Turner; S Taylor; P B Tchounwou
Journal:  Environ Toxicol       Date:  2017-01-27       Impact factor: 4.119

6.  Transcriptional survey of alveolar macrophages in a murine model of chronic granulomatous inflammation reveals common themes with human sarcoidosis.

Authors:  Arjun Mohan; Anagha Malur; Matthew McPeek; Barbara P Barna; Lynn M Schnapp; Mary Jane Thomassen; Sina A Gharib
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-06       Impact factor: 5.464

7.  PPAR-gamma pathways attenuate pulmonary granuloma formation in a carbon nanotube induced murine model of sarcoidosis.

Authors:  Matthew McPeek; Anagha Malur; Debra A Tokarz; Gina Murray; Barbara P Barna; Mary Jane Thomassen
Journal:  Biochem Biophys Res Commun       Date:  2018-06-15       Impact factor: 3.575

8.  Impaired mitochondrial function of alveolar macrophages in carbon nanotube-induced chronic pulmonary granulomatous disease.

Authors:  Eman Soliman; Ahmed E M Elhassanny; Anagha Malur; Matthew McPeek; Aaron Bell; Nancy Leffler; Rukiyah Van Dross; Jacob L Jones; Achut G Malur; Mary Jane Thomassen
Journal:  Toxicology       Date:  2020-09-22       Impact factor: 4.221

9.  Identification of the Core MicroRNAs and Potential Molecular Mechanismsin Sarcoidosis Using Bioinformatics Analysis.

Authors:  Yuan Cao; Hua Zhang; Lulu Zheng; Qiao Li
Journal:  Front Mol Biosci       Date:  2021-05-13

10.  Inflammatory Pathways in Sarcoidosis.

Authors:  Barbara P Barna; Marc A Judson; Mary Jane Thomassen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.